



September 22, 2021

Mr. Farruq Jafery  
Vice President, Pricing, Contract Operations & Reimbursement  
Novo Nordisk, Inc.  
800 Scudders Mill Road  
Plainsboro, New Jersey 08536

Dear Mr. Jafery:

By letter dated May 17, 2021, HRSA instructed Novo Nordisk, Inc. (Novo Nordisk) to comply with its 340B statutory obligations and to immediately begin offering Novo Nordisk's covered outpatient drugs at the 340B ceiling price to covered entities that dispense the discounted medications through their contract pharmacy arrangements. HRSA informed Novo Nordisk that continued failure to provide the 340B price to covered entities utilizing contract pharmacies could result in civil monetary penalties.

Given Novo Nordisk's continued refusal to comply,<sup>1</sup> HRSA has referred this issue to the HHS Office of the Inspector General (OIG) in accordance with the 340B Program Ceiling Price and Civil Monetary Penalties Final Rule.<sup>2</sup>

Sincerely,

/Michelle Herzog/

Michelle Herzog  
Acting Director  
Office of Pharmacy Affairs

<sup>1</sup> Novo Nordisk provided HRSA its basis for refusing to comply in a letter dated June 1, 2021.

<sup>2</sup> 82 Fed. Reg. 1210, 1230 (Jan. 5, 2017); 42 C.F.R. §10.11(a)